Cargando…
Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity
BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117984/ https://www.ncbi.nlm.nih.gov/pubmed/37090702 http://dx.doi.org/10.3389/fimmu.2023.1114808 |
_version_ | 1785028709885935616 |
---|---|
author | Firl, Christina E. M. Halushka, Marc Fraser, Nicola Masson, Mala Cuneo, Bettina F. Saxena, Amit Clancy, Robert Buyon, Jill |
author_facet | Firl, Christina E. M. Halushka, Marc Fraser, Nicola Masson, Mala Cuneo, Bettina F. Saxena, Amit Clancy, Robert Buyon, Jill |
author_sort | Firl, Christina E. M. |
collection | PubMed |
description | BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibroblasts encourages re-examination of existing models with the consideration of multiple fibroblast subtypes (and their unique functional differences) in mind. This study addressed fibroblast heterogeneity by examining expression of α-Smooth Muscle Actin (myofibroblasts) and of S100 Calcium-Binding Protein A4 (S100A4). METHODS: Using a previously established model of rheumatic scarring/fibrosis in vitro, supported by the evaluation of cord blood from cardiac-NL neonates and their healthy (anti-SSA/Ro-exposed) counterparts, and autopsy tissue from fetuses dying with cardiac-NL, the current study was initiated to more clearly define and distinguish the S100A4-positive fibroblast in the fetal cardiac environment. RESULTS: S100A4 immunostaining was observed in 4 cardiac-NL hearts with positional identity in the conduction system at regions of dystrophic calcification but not fibrotic zones, the latter containing only myofibroblasts. In vitro, fibroblasts cultured with supernatants of macrophages transfected with hY3 (noncoding ssRNA) differentiated into myofibroblasts or S100A4(+) fibroblasts. Myofibroblasts expressed collagen while S100A4(+) fibroblasts expressed pro-angiogenic cytokines and proteases that degrade collagen. Cord blood levels of S100A4 in anti-SSA/Ro-exposed neonates tracked disease severity and, in discordant twins, distinguished affected from unaffected. CONCLUSIONS: These findings position the S100A4(+) fibroblast alongside the canonical myofibroblast in the pathogenesis of cardiac-NL. Neonatal S100A4 levels support a novel biomarker of poor prognosis. |
format | Online Article Text |
id | pubmed-10117984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101179842023-04-21 Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity Firl, Christina E. M. Halushka, Marc Fraser, Nicola Masson, Mala Cuneo, Bettina F. Saxena, Amit Clancy, Robert Buyon, Jill Front Immunol Immunology BACKGROUND: Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. OBJECTIVES: Increased appreciation of heterogeneity in fibroblasts encourages re-examination of existing models with the consideration of multiple fibroblast subtypes (and their unique functional differences) in mind. This study addressed fibroblast heterogeneity by examining expression of α-Smooth Muscle Actin (myofibroblasts) and of S100 Calcium-Binding Protein A4 (S100A4). METHODS: Using a previously established model of rheumatic scarring/fibrosis in vitro, supported by the evaluation of cord blood from cardiac-NL neonates and their healthy (anti-SSA/Ro-exposed) counterparts, and autopsy tissue from fetuses dying with cardiac-NL, the current study was initiated to more clearly define and distinguish the S100A4-positive fibroblast in the fetal cardiac environment. RESULTS: S100A4 immunostaining was observed in 4 cardiac-NL hearts with positional identity in the conduction system at regions of dystrophic calcification but not fibrotic zones, the latter containing only myofibroblasts. In vitro, fibroblasts cultured with supernatants of macrophages transfected with hY3 (noncoding ssRNA) differentiated into myofibroblasts or S100A4(+) fibroblasts. Myofibroblasts expressed collagen while S100A4(+) fibroblasts expressed pro-angiogenic cytokines and proteases that degrade collagen. Cord blood levels of S100A4 in anti-SSA/Ro-exposed neonates tracked disease severity and, in discordant twins, distinguished affected from unaffected. CONCLUSIONS: These findings position the S100A4(+) fibroblast alongside the canonical myofibroblast in the pathogenesis of cardiac-NL. Neonatal S100A4 levels support a novel biomarker of poor prognosis. Frontiers Media S.A. 2023-04-06 /pmc/articles/PMC10117984/ /pubmed/37090702 http://dx.doi.org/10.3389/fimmu.2023.1114808 Text en Copyright © 2023 Firl, Halushka, Fraser, Masson, Cuneo, Saxena, Clancy and Buyon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Firl, Christina E. M. Halushka, Marc Fraser, Nicola Masson, Mala Cuneo, Bettina F. Saxena, Amit Clancy, Robert Buyon, Jill Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title | Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title_full | Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title_fullStr | Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title_full_unstemmed | Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title_short | Contribution of S100A4-expressing fibroblasts to anti-SSA/Ro-associated atrioventricular nodal calcification and soluble S100A4 as a biomarker of clinical severity |
title_sort | contribution of s100a4-expressing fibroblasts to anti-ssa/ro-associated atrioventricular nodal calcification and soluble s100a4 as a biomarker of clinical severity |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117984/ https://www.ncbi.nlm.nih.gov/pubmed/37090702 http://dx.doi.org/10.3389/fimmu.2023.1114808 |
work_keys_str_mv | AT firlchristinaem contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT halushkamarc contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT frasernicola contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT massonmala contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT cuneobettinaf contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT saxenaamit contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT clancyrobert contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity AT buyonjill contributionofs100a4expressingfibroblaststoantissaroassociatedatrioventricularnodalcalcificationandsolubles100a4asabiomarkerofclinicalseverity |